{
    "clinical_study": {
        "@rank": "158048", 
        "acronym": "IMPACT-24Bt", 
        "arm_group": [
            {
                "arm_group_label": "Active Stimulation", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sham Stimulation", 
                "arm_group_type": "Sham Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to assess the safety and effectiveness of SPG\n      stimulation with the ISS in a 24 hour window, in patients with an acute ischemic stroke in\n      the anterior circulation, who received IV-rtPA and Standard of Care."
        }, 
        "brief_title": "THE IMPACT- 24Bt Post rtPA TRIAL (IMPlant Augmenting Cerebral Blood Flow Trial 24 Hours From Stroke Onset, Post IV-rtPA)", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age: \u2265 40 years and \u2264 80 years for male and 85 for female subjects\n\n          2. Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior\n             Cerebral Artery territories in the left cerebral hemisphere\n\n          3. Imaging findings demonstrating signs of ischemia in the anterior circulation\n\n          4. Administration of IV-rtPA within \u2264 4.5 hours from stroke onset\n\n          5. NIHSS \u2265 7 and \u2264 18 and clinical signs of aphasia (NIHSS best language score \u2265 1)\n\n          6. Ability to initiate treatment within \u2264 24 hours from stroke onset\n\n          7. Signed informed consent from patient him/herself or legally authorized representative\n             if applicable\n\n        Exclusion Criteria:\n\n          1. Neuro-imaging evidence of any intracranial hemorrhage or hemorrhagic transformation\n\n          2. Massive stroke\n\n          3. Acute stroke due to lacunar infarct\n\n          4. Acute stroke in the Posterior circulation\n\n          5. Minor stroke\n\n          6. Bilateral stroke\n\n          7. Treated with IA-rtPA or neurothrombectomy devices for the current stroke\n\n          8. NIHSS level of consciousness score \u2265 2\n\n          9. Previous stroke in the last 6 months\n\n         10. Pre-existing disability; Pre-existing Modified Rankin Score >1\n\n         11. Patients with bleeding propensity\n\n         12. Known cerebral arteriovenous malformation, cerebral aneurysm\n\n         13. Seizures at onset\n\n         14. Clinical suspicion of septic embolus\n\n         15. Uncontrolled hypertension (systolic >185 mmHg and/or diastolic >110 mmHg)\n\n         16. Serious systemic infection.\n\n         17. Women known to be pregnant or having a positive or indeterminate pregnancy test\n\n         18. Patients with other implanted neural stimulator/ electronic devices (pacemakers)\n\n         19. History of SPG ablation ipsilateral to the stroke side.\n\n         20. Any condition in the oral cavity that prevents implantation of the INS\n\n         21. Life expectancy < 1 year from causes other than stroke.\n\n         22. Participating in any other therapeutic investigational trial within the last 30 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874093", 
            "org_study_id": "CLP1050035"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active Stimulation", 
                "description": "SPG stimulation and standard of care", 
                "intervention_name": "The Ischemic Stroke System", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Sham Stimulation", 
                "description": "Sham stimulation and standard of care", 
                "intervention_name": "Sham control", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "0029"
                    }, 
                    "name": "Helsinki University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Vall d'Hebron"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Finland", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Safety and Effectiveness of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects With Acute Ischemic Stroke", 
        "overall_contact": {
            "email": "noamz@brainsgate.com", 
            "last_name": "Noam Zilberman"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Finland: Valvira - National Supervisory Authority for Welfare and Health", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary effectiveness endpoint will be the modified Rankin Scale (mRS) evaluated by the site on Day 90\u00b17.\nThe statistical analysis of the primary effectiveness endpoint will be: Sliding Dichotomous mRS.", 
            "measure": "Distribution of patients across the ordinal modified Rankin scale (mRS)", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874093"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary effectiveness endpoint will be the modified Rankin Scale (mRS) evaluated by the site on Day 90\u00b17 for patients with NIHSS best language score \u2265 2 at screening.\nThe statistical analysis of the primary effectiveness endpoint will be: Sliding Dichotomous mRS.", 
            "measure": "Distribution of patients with NIHSS best language score \u2265 2 at screening across the ordinal modified Rankin scale (mRS)", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "source": "BrainsGate", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BrainsGate", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}